Condition (MeSH)
Dysgammaglobulinemia
ClinicalTrials.gov lists 32 trials for Dysgammaglobulinemia or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Dysgammaglobulinemia trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 4 |
| 2012 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dysgammaglobulinemia trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 3 | 8 |
| Phase 4 | 3 |
| Not applicable | 3 |
| Observational | 9 |
How many Dysgammaglobulinemia trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 19 |
| Terminated | 2 |
| Unknown status | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dysgammaglobulinemia trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CSL Behring | 3 |
| National Human Genome Research Institute (NHGRI) | 2 |
| Celldex Therapeutics | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| FFF Enterprises | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Dysgammaglobulinemia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 2 |
| Busulfan | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Globulin, Immune | 4 |
| Immunoglobulins Intravenous (Human) | 3 |
| Hematopoietic Stem Cell Transplant | 2 |
| AG chemotherapy | 1 |
| Flebogamma 5% DIF | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dysgammaglobulinemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac arrest | 2 | 1 |
| Cellulitis | 2 | 2 |
| Respiratory failure | 2 | 1 |
| Sepsis | 2 | 1 |
| left lower lobe pneumonia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Dysgammaglobulinemia? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. | European journal of haematology | 2021 | Yes |
| Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. | QJM : monthly journal of the Association of Physicians | 2014 | Yes |
| Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. | Current opinion in allergy and clinical immunology | 2006 | Yes |
| Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. | Proceedings of the National Academy of Sciences of the United States of America | 1989 | Yes |
| Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. | International journal of hematology | 2016 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.